FDA Clears Darunavir (Prezista) for Pregnant Women With HIV FDA Clears Darunavir (Prezista) for Pregnant Women With HIV

Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

Related Links:

Conclusion: Availability and accessibility of PMTCT programme services are still problematic. The study has the potential to inform development of strategies that may facilitate access to care for PMTCT programme clients. PMID: 32200723 [PubMed - in process]
Source: African Journal of AIDS Research - Category: African Health Tags: Afr J AIDS Res Source Type: research
Authors: Mathad JS, LaCourse SM, Gupta A PMID: 32202066 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
.
Source: AIDS Care - Category: Infectious Diseases Authors: Source Type: research
Source: Therapeutics and Clinical Risk Management - Category: Drugs & Pharmacology Tags: HIV/AIDS - Research and Palliative Care Source Type: research
CONCLUSIONS: Experiences from the PROMISE study illustrate the challenges of enrolling in longer term studies in the setting of rapidly evolving prevention and treatment standards priorities. The lessons learned will help the community, site investigators, and study coordinators in the design and implementation of future clinical trials. PMID: 32191142 [PubMed - as supplied by publisher]
Source: Clinical Trials - Category: Research Authors: Tags: Clin Trials Source Type: research
Objective: To investigate factors contributing to preterm birth (PTB), including cART use and clinical and social determinants of health, in women living with HIV (WLWH) from British Columbia, Canada. Design: Retrospective observational cohort. Methods: We investigated the effect of cART use and other clinical and demographic factors on spontaneous PTB (sPTB) rates (
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Objectives: Measuring retention is critical for antiretroviral therapy (ART) management and program monitoring; however, many definitions and data sources, usually from single health facilities, are used. We used routine electronic data, linked across facilities, to examine the impact of definitions and data sources on retention estimates among women in Cape Town, South Africa. Design: Retrospective cohort study. Methods: We compiled routine electronic laboratory, pharmacy and clinic visit data for 617 women who started ART during pregnancy (2013–2014) and estimated 24-month retention using different definiti...
Source: AIDS - Category: Infectious Diseases Tags: Epidemiology and Social Source Type: research
Conclusion: Substantial HIV incidence among pregnant and breast-feeding women in SSA, even in the current era of combination HIV prevention and treatment, underscores the need for prevention tailored to high-risk pregnant and breast-feeding women.
Source: AIDS - Category: Infectious Diseases Tags: Epidemiology and Social Source Type: research
Authors: Kalinjuma AV, Glass TR, Weisser M, Myeya SJ, Kasuga B, Kisung'a Y, Sikalengo G, Katende A, Battegay M, Vanobberghen F, KIULARCO Study Group Abstract INTRODUCTION: Lifelong antiretroviral therapy (ART) improves health outcomes for HIV-positive individuals, but is jeopardized by irregular clinic attendance and hence poor adherence. Loss to follow-up (LTFU) is typically defined retrospectively but this may lead to biased inferences. We assessed incidence of and factors associated with LTFU, prospectively and accounting for recurrent LTFU episodes, in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) o...
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
Authors: Kerschberger B, Schomaker M, Jobanputra K, Kabore SM, Teck R, Mabhena E, Mthethwa-Hleza S, Rusch B, Ciglenecki I, Boulle A Abstract INTRODUCTION: The Treat-All policy - antiretroviral therapy (ART) initiation irrespective of CD4 cell criteria - increases access to treatment. Many ART programmes, however, reported increasing attrition and viral failure during treatment expansion, questioning the programmatic feasibility of Treat-All in resource-limited settings. We aimed to describe and compare programmatic outcomes between Treat-All and standard of care (SOC) in the public sectors of Eswatini. METHODS:...
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
More News: Drugs & Pharmacology | HIV AIDS | Norvir | Pregnancy | Prezista | Women